Abstract
The treatment of disseminated breast cancer consists first of modification of the hormonal environment of the patient. This can be done either by hormonal deprivation — oophorectomy, adrenalectomy, or hypophysectomy — or by the administration of hormones, usually steroids, androgens, estrogens, and corticosteroids. Only when these therapeutic measures have failed is it advisable to have recourse to non-hormonal cytotoxic agents, such as the alkylating drugs and 5-fluorouracil. One exception to this rule may be the group of patients less than one year postmenopausal. These are notoriously resistant to hormonal manipulation, whether surgical (hormonal deprivation) or medical (hormonal administration). This is why a clinical investigation is now being conducted with the aim of discovering whether the use of 5-fluorouracil or of some alkylating agent should precede hormone treatment in this particular group of patients, as the only exception to the general rule.
This work was supported by Grant Ca 4896-03 of the National Institutes of Health, Bethesda, Md., United States of America, for a co-operative study organized in Europe, and by Contract Euratom-ULB-Pise no. 026-63-4 BIAC. The European Breast Cancer Group is now part of the Groupe Européen de Chimiothérapie anti-cancéreuse.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Bloom, H. J. G.: Natural history of untreated breast cancer. Ann. N. Y. Acad. Sci. 114, 747 (1964).
Bulbrook, R. D.: Hormone assays in human breast cancer. Vit. and Horm. 23, 329 (1965).
Dao, T. L., and E. Tan: A comparative evaluation of adrenalectomy and androgens in advanced mammary cancer. Cancer Chemother. Rep. 16, 309 (1962).
European Breast Cancer Group: Testosterone propionate therapy of breast cancer: a progress report. Cancer Chemother. Rep. 16, 273 (1962).
European Breast Cancer Group: Study No. 3 (to be published).
Groupe Européen du Cancer du Sein (Coordinateur: H. J. Tagnon): Le traitement hormonal du cancer du sein en phase avancée. Comparaison des résultats obtenus au moyen de la delta-1-testololactone et du propionate de testostérone. Rev. franç. Etud. clin. biol. 7, 1067 (1962).
Groupe Européen du Cancer du Sein (Coordinateur: H. J. Tagnon): Le traitement hormonal du cancer du sein en phase avancée. Comparaison entre le propionate de testostérone et la combinaison propionate de testosterone — delta-1-testololactone. Rev. franç. Etud. clin. biol. 9, 88 (1964).
Huggins, C. B.: Propositions in hormonal treatment of advanced cancers. J. Amer. med. Ass. 192, 1141 (1965).
Karhausen, L., Y. Kenis, J. Smulders, et R. Parmentier: Hypercalcémie et néphrocalcinose: étude de 4 cas de cancer du sein avec métastases osseuses. Acta clin. belg. 10, 296 (1955).
Kenis, Y., P. Dustin, J. A. Henry, et H. J. Tagnon: Action du Myleran dans 22 cas de leucémie myéloïde chronique. Rev. franç. Etud. clin. biol. 1, 435 (1956).
Kennedy, B. J.: Massive estrogen administration in premenopausal women with advanced breast cancer. Cancer Chemother. Rep. 16, 283 (1962).
MacDonald, I.: Endocrine ablation in disseminated mammary carcinoma. Surg. Gynec. Obstet. 115, 215 (1962).
Nissen Meyer, R., and J. H. Vogt: Cortisone treatment of metastatic breast cancer. Acta Un. int. Cancr. 15, 2240 (1959).
Pearson, O. H.: Observations on the role of androgens and estrogens in body balance. Arch. intern. Med. 100, 724 (1957).
Segaloff, A.: Testosterone propionate therapy of breast cancer. A report for the cooperative breast cancer group. In Pincus, G., and E. P. Vollmer (ed.): Biological activities of steroids in relation to cancer. New York and London: Academic Press 1960.
Segaloff, A. et al.: Study No. 2 of the Cooperative Breast Cancer Group. Cancer Chemother. Rep. 11, 109 (1961).
Segaloff, A. et al.: Breast cancer. St. Louis: C.V. Mosby: 1958, pages 193–195.
Tagnon, H. J., P. Shulman, W. F. Whitmore, and L. A. Leone: Prostatic fibrinolysin. Role in hemorrhagic diathesis of cancer of the prostate. Amer. J. Med. 15, 875–884 (1953).
Tagnon, H. J., P. Shulman, W. F. Whitmore, and L. A. Leone: Traitement hormonal du cancer du sein en phase avancée. Brux. méd. 41, 817 (1961).
Tagnon, H. J., and A. Steens-Lievens: Studies of fibrinolysis and acid phosphatase in cancer of the prostate. Biology of the prostate and related tissues. Washington: National Cancer Institute 1963 (Monograph No. 12).
Tagnon, H. J., and A. Steens-Lievens: La dépendance hormonale dans les cancers mammaires. Méd. et Hyg. (Genève) 22, 1001 (1964 a).
Tagnon, H. J., and A. Steens-Lievens: Clinical results with hormones in disseminated mammary cancer. In Plattner, P. A. (ed.): Chemotherapy of cancer. Amsterdam and New York: Elsevier 1964 b.
Van Gilse, H. A.: Long term treatment with corticosteroids of patients with metastatic breast cancer. Cancer Chemother. Rep. 16, 293 (1962).
Van Rymenant, M., A. Coune, H. J. Tagnon, et S. Simon: Le traitement hormonal du cancer du sein en phase avancée. Méthodes d’étude: comparaison de la delta-1-testololactone avec le propionate de testostérone. Acta clin. belg. 18, 469 (1963).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1967 Springer-Verlag Berlin · Heidelberg
About this chapter
Cite this chapter
Tagnon, H.J., Coune, A., Heuson, J.C., van Rymenant, M. (1967). Problems in the Treatment of Disseminated Cancer of the Breast: Selection of Patients for Hormone Treatment. In: Manuila, L., Moles, S., Rentchnick, P. (eds) New Trends in the Treatment of Cancer. Recent Results in Cancer Research / Fortschritte der Krebsforschung / Progrès dans les recherches sur le cancer, vol 8. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-87620-2_6
Download citation
DOI: https://doi.org/10.1007/978-3-642-87620-2_6
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-87622-6
Online ISBN: 978-3-642-87620-2
eBook Packages: Springer Book Archive